<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390973</url>
  </required_header>
  <id_info>
    <org_study_id>Remission</org_study_id>
    <nct_id>NCT02390973</nct_id>
  </id_info>
  <brief_title>Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)</brief_title>
  <acronym>REMISSION</acronym>
  <official_title>Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Medical Products</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery procedures induce weight loss through restriction and/or malabsorption. The
      mechanisms underlying type 2 diabetes remission and others metabolic improvements after
      Roux-en-Y Gastric Bypass (RYGB), sleeve gastrectomy (SG) or biliopancreatic diversion with
      duodenal switch (BPD-DS) have not yet been formally studied. The investigators propose a
      longitudinal study with the overall objective of measuring the long-term impact of these
      three bariatric surgeries (RYGB, SG, BPD-DS) on metabolic, renal and cardiovascular fate in
      patients with type 2 diabetes. The investigators overall hypothesis is that some bariatric
      procedures generate hitherto unrecognized effects on many disease-related outcomes, which
      greatly contributes to their beneficial impact in diabetic patients. The investigators
      propose 3 specific aims: 1) to establish the long term effect of the three surgeries on the
      metabolic recovery and quality of life in groups of diabetic patients treated with insulin,
      hypoglycemic agents or diet; 2) to establish the long term impact of the three surgeries on
      renal and cardiovascular functions in subgroup of patients with these conditions; 3) to
      compare metabolic impact of surgeries to those of best medical care for diabetes in a
      non-surgical control group. For most severely obese patients, lifestyle interventions,
      perhaps effective in inducing short-lived weight losses, are ineffective for long-term weight
      loss maintenance and durable metabolic recovery. The increasing popularity of obesity
      surgeries calls for a better understanding of the underlying mechanisms. This is especially
      true and urgent when considering that knowledge on the relative impact of each procedure
      (i.e. SG vs. RYGB and BPD-DS) in resolving T2D is still limited. Better knowledge on each of
      the procedures will allow stronger scientific rationale for selecting the right surgery for
      the right patient and improve care for the severely obese individual.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 2 diabetes remission rate</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>percent of patient achieving type 2 diabetes remission in each groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microalbuminuria</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>Normalisation of A/C ratio after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinopathy</measure>
    <time_frame>from baseline up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension remission rate</measure>
    <time_frame>from baseline up yo 60 months</time_frame>
    <description>percent of patient achieving hypertension remission in each groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GERD remission rate</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>percent of patient achieving gastro-esophageal reflux disease resolution in each groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>quality of life after surgery eveluated with questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep apnea remission rate</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>percent of patient achieving sleep apnea remission in each groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>weight loss (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression of liver disease</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>regression of liver disease documented by percutaneous liver biopsy after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dislipidemia remission</measure>
    <time_frame>from baseline up to 60 months</time_frame>
    <description>percent of patient achieving dislipidemia remission in each groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>short-term complications</measure>
    <time_frame>baseline up to 4 month</time_frame>
    <description>comparaison of intra-operative, post-operative and in-hospital complications between groups using clavien classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term complications</measure>
    <time_frame>baseline up to 60 months</time_frame>
    <description>Vital status and long-term complications including cardiovascular events, micro- or macro-vascular complications, cancer, psychiatric events, bone fractures, operations, readmission related or unrelated to the surgery, changes in medical treatment will be compared between groups</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y Gastric Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliopancreatic Diversion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the best medical management of their diabetes, non-surgical group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve Gastrectomy</intervention_name>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y Gastric Bypass</intervention_name>
    <arm_group_label>Roux-en-Y Gastric Bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biliopancreatic Diversion with Duodenal Switch</intervention_name>
    <arm_group_label>Biliopancreatic Diversion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical management</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 35

          -  type 2 diabetes

          -  HbA1c ≥ 6,5 % or fasting glycemia ≥7mmol/l or non-fasting glycemia ≥11mmol/l

          -  able to consent

        Exclusion Criteria:

          -  pregnancy

          -  past esophageal, gastric or bariatric surgery

          -  irritable bowel, unexplained intermittent vomiting, severe abdominal pain, chronic
             diarrhea or constipation

          -  history of gastric or duodenal ulcers

          -  pre-operatory hypoalbuminemy

          -  history of renal, hepatic, cardiac or pulmonary severe disease

          -  taken of corticosteroid in the last month

          -  evidence of psycological problem that may affect the capacity to understand the
             project and to comply with the medical recommandations

          -  history of drug use or alcool abuse in the last 12 months

          -  history of gastro-intestinal inflammatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melanie Nadeau, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3490</phone_ext>
    <email>melanie.nadeau@criucpq.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Nadeau, MSc</last_name>
      <phone>418-565-8711</phone>
      <phone_ext>3490</phone_ext>
      <email>melanie.nadeau@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Suzy Laroche</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>4810</phone_ext>
      <email>suzy_laroche@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Biertho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Tchernof, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Dube, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Poirier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Laurent Biertho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

